Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease

[1]  Hugh Gallagher,et al.  Chronic kidney disease in adults: assessment and management. , 2020, Clinical medicine.

[2]  J. Pell,et al.  Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease , 2019, Circulation.

[3]  D. Brancaccio,et al.  Detecting high-risk chronic kidney disease-mineral bone disorder phenotypes among patients on dialysis: a historical cohort study. , 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  M. Woodward,et al.  Predicting timing of clinical outcomes in patients with chronic kidney disease and severely decreased glomerular filtration rate. , 2018, Kidney international.

[5]  Yuekang Xu,et al.  Involvement of cystatin C in immunity and apoptosis , 2018, Immunology Letters.

[6]  B. Astor,et al.  Risk Factors for Prognosis in Patients With Severely Decreased GFR , 2018, Kidney international reports.

[7]  Reporting for specific materials, systems and methods , 2018 .

[8]  Jackson T. Wright,et al.  Effects of Intensive BP Control in CKD. , 2017, Journal of the American Society of Nephrology : JASN.

[9]  C. Sudlow,et al.  Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population , 2017, American journal of epidemiology.

[10]  J. Hippisley-Cox,et al.  Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study , 2017, British Medical Journal.

[11]  C. Soulage,et al.  Aryl Hydrocarbon Receptor Activation in Chronic Kidney Disease: Role of Uremic Toxins , 2017, Nephron.

[12]  Chava L. Ramspek,et al.  Prediction versus aetiology: common pitfalls and how to avoid them: Clinical Epidemiology in Nephrology , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  R. Collins,et al.  Are statins useful in patients with advanced chronic kidney disease? - Authors' reply. , 2016, The lancet. Diabetes & endocrinology.

[14]  M. Landray,et al.  Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. , 2016, The lancet. Diabetes & endocrinology.

[15]  F. Hobbs,et al.  Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis , 2016, PloS one.

[16]  C. Escobar Cervantes,et al.  [A randomized trial of intensive versus standard blood pressure control]. , 2016, Semergen.

[17]  A. Hoes,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.

[18]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[19]  M. Woodward,et al.  Kidney measures beyond traditional risk factors for cardiovascular prediction: A collaborative meta-analysis , 2015, The lancet. Diabetes & endocrinology.

[20]  M. Woodward,et al.  Kidney measures beyond traditional risk factors for cardiovascular prediction: A collaborative meta-analysis , 2015, The lancet. Diabetes & endocrinology.

[21]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[22]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[23]  K. Khunti,et al.  The eGFR-C study: accuracy of glomerular filtration rate (GFR) estimation using creatinine and cystatin C and albuminuria for monitoring disease progression in patients with stage 3 chronic kidney disease - prospective longitudinal study in a multiethnic population , 2014, BMC Nephrology.

[24]  João Victor Salgado,et al.  How to understand the association between cystatin C levels and cardiovascular disease: Imbalance, counterbalance, or consequence? , 2013, Journal of cardiology.

[25]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[26]  Josef Coresh,et al.  Cystatin C versus creatinine in determining risk based on kidney function. , 2013, The New England journal of medicine.

[27]  M. Shlipak,et al.  Update on cystatin C: incorporation into clinical practice. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[28]  Chi Pang Wen,et al.  Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention , 2013, The Lancet.

[29]  F. Kronenberg,et al.  Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis , 2013, BMJ.

[30]  Munir Pirmohamed,et al.  Drug-grapefruit juice interactions , 2013, BMJ.

[31]  Brenda R. Hemmelgarn,et al.  Notice , 2012, Kidney International Supplements.

[32]  P. Elliott,et al.  UK Biobank: Current status and what it means for epidemiology , 2012 .

[33]  Harold I Feldman,et al.  Estimating glomerular filtration rate from serum creatinine and cystatin C. , 2012, The New England journal of medicine.

[34]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[35]  M. Landray,et al.  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial , 2011, The Lancet.

[36]  S. Yusuf,et al.  Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. , 2011, Kidney international.

[37]  N. Tangri,et al.  A predictive model for progression of chronic kidney disease to kidney failure. , 2011, JAMA.

[38]  M. Woodward,et al.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.

[39]  A. Israni,et al.  Predicting Coronary Heart Disease after Kidney Transplantation: Patient Outcomes in Renal Transplantation (PORT) Study , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[40]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[41]  D. de Zeeuw,et al.  First morning voids are more reliable than spot urine samples to assess microalbuminuria. , 2009, Journal of the American Society of Nephrology : JASN.

[42]  P. Elliott,et al.  The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. , 2008, International journal of epidemiology.

[43]  A. Levin,et al.  Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. , 2007, Kidney international.

[44]  W Greg Miller,et al.  Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. , 2006, Clinical chemistry.

[45]  A. Hoes,et al.  [Guidelines on cardiovascular disease prevention in clinical practice]. , 2005, Revue medicale de Liege.

[46]  Philippe Amouyel,et al.  α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[47]  Charles E McCulloch,et al.  Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.

[48]  Philippe Amouyel,et al.  Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. , 2004, Lancet.

[49]  Shah Ebrahim,et al.  JOINT ESC GUIDELINES 2016 European Guidelines on cardiovascular disease prevention in clinical practice – Web Addenda , 2016 .

[50]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Circulation.

[51]  Bertram L Kasiske,et al.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Hypertension.

[52]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. , 2003 .

[53]  B. Kasiske,et al.  Cardiovascular disease after renal transplantation. , 2000, Journal of the American Society of Nephrology : JASN.

[54]  W. G. Walker,et al.  Plasma aldosterone regulation in anephric man. , 1973, Kidney international.